Skip to Menu Skip to Search Contact Us Skip to Content
US Flag

You are accessing SGS’s website from the USA.

Visit the US website instead

Stay on the global website and remember my choice

Over the last 30 years and thousands of early phase trials execution, SGS has acquired a unique expertise in early phase healthy subjects and patients clinical trials.

From drug development consultancy, preclinical data analysis, study design and first in human (FIH), to exploratory trials and proof of concept studies, we are pleased to share, through the following Maxims, the early phase clinical trial drug development fundamentals.

Early Phase Clinical Trials - Maxim #1

  • Maxim#1 Study Design

    Analyze all pre-clinical data and optimize the study design

    The moment when a new compound is ready to be tested in humans is exciting but challenging. It means the drug has successfully passed a battery of pre-clinical tests, but based on these, many important decisions for its clinical development need to be made such as:

    • Safety conditions of the trial for the volunteers
    • Study feasibility
    • Biomarker choices

    To predict a drug’s behavior in humans, all relevant pre-clinical data should be thoroughly analyzed. Often, more data is needed than what is strictly required by the regulators depending on the pharmacological and safety profile. For study design there is also not one-size-fits all.

    To learn more about how to analyze all pre-clinical data, and optimize study design with concrete case studies:

  • Maxim#2 Regulatory Proofed

    Working closely with regulators is a key strategy for successful drug development, not a barrier to be sidestepped or overcome.

    Building regulatory advice into a trial program is an effective strategy to mitigate the regulatory risk inherent in product development and improve the likelihood of early product approval.

    Requesting scientific advice from the right regulatory body at the right time has become an essential tool to guide product development and to have answer on many aspects of the development program:

    • Have I chosen the correct and most appropriate animal model? And if there is no pre-defined animal model, is my proposal appropriate?
    • Is the manufacturing process well defined and appropriate?
    • Have I well classified my IMP?
    • Have I selected the appropriate comparator for my patient studies? Placebo/other treatment?
    • Are there financial incentives for small and medium-sized enterprises (SMEs) to seek scientific advice from the European Medicines Agency (EMA)? How does it work with the US Food and Drug Administration (FDA)?

    To learn more about scientific advices from regulators with concrete case studies:

  • Maxim#3 Consider Modeling & Simulation

    Careful decision making is essential to minimize clinical development time, manage costs and improve the probability of commercial success.

    Modeling and simulation (M&S) can be a very useful strategy to mitigate risks and to make better informed decisions.

    M&S involves modeling compounds, mechanisms and disease level data based on historical observations and existing real life data. Computer simulations are run on these models to generate information that can be used to predict outcomes, thereby improving the quality, efficiency and cost-effectiveness of decision-making, both for internal and regulatory purposes.

    M&S can be of help in several areas of drug development:

    • Can I optimize the starting dose of my first-in-human trial by extrapolating non-clinical data?
    • Is it possible to accurately estimate complex drug-drug interaction (DDI) profiles of a compound in silico and explore its potential effects on, for example, cytochrome P450 enzyme (CYP)?
    • Could the inhibitor effect at the site of metabolism (gut, liver, or any tissue) be predicted?
    • Can I predict drug behavior in pediatric patient populations to support a pediatric investigation plan (PIP), based on my existing adult data?

    To further discover Modeling & Simulations uses in early phase clinical trials with concrete case studies:

  • Maxim#4 Managing Time & Risk – Remember Murphy and Hofstadter

    “If anything can go wrong, it will go wrong” and “everything takes longer than expected” are two important laws by Murphy and Hofstadter, two eminent researchers into time and risk management, that also apply in clinical research.

    When planning a trial, one should keep in mind that things do not always go smoothly. Early phase clinical trial protocols tend to become more and more complex, focusing on gaining as much scientific insight as possible.

    Many study aspects need to be evaluated from a practical point of view. These include:

    • The recruitability of the exact study population
    • Investigational Medicinal Product (IMP) preparation steps
    • The use of sentinel dosing groups

    For a successful trial execution and to learn more about Time and Risk management through efficient protocol design read our two new case studies:

  • Maxim#5 Recruiting the Studied Population in a Timely Manner

    Recruitment and retention issues result in trial delays and costs and may potentially undermine trial results.

    Every clinical trial phase is facing its own specific hurdles. The fact that early phase trials do not offer therapeutic benefit for the subjects is a specific drawback. Phase 1 trials are typically performed in healthy volunteers, whereas from phase 2 onwards patient populations are needed. However, special populations and patient cohorts are increasingly included early on.

    To assure recruitment in a timely manner it is important to tackle hurdles at all stages of trial preparation and execution and respect the following measures:

    • Simplify the protocol if possible to lower the burden for patients and physicians
    • Evaluate eligibility criteria to identify overly restrictive components
    • Identify factors that impact recruitment, both positively and negatively
    • Foresee a realistic recruitment period, leave some flexibility

    To ensure efficient subject recruitment for your study, read our complete technical bulletin with two case studies:

  • Maxim#6 Innovation Powers Research & Development

    To estimate a drug’s clinical potential, information on safety, pharmacokinetic and pharmacodynamic outcomes are all paramount.

    The development of new pharmacological compounds can be lengthy and very costly, with many failure risks even during later phase clinical trials. Via translational approaches, including innovative techniques such as human challenge modelling and relevant biomarkers, critical information on a compound’s dose-response effect can be acquired in the early clinical phase.

    However, these render phase 1 trials more complex and challenging. An experienced team must assess the following points:

    • The research question must be clearly justified and weighed to alternative methodologies
    • The proposed methods must be appropriate and provide a meaningful, valid answer
    • The method must be as safe as possible and appropriate management of possible risks in place

    To learn more about innovative techniques with a concrete case study:

  • Maxim#7 Respect the Rules of the Protocol

    The clinical trial protocol, as a detailed outline of a clinical study, must be rigorously followed by the clinical trial team, not only to be in line with regulations, but also to avoid harm to participants and erroneous conclusions.

    As early phase trials are becoming increasingly complex, the risk of protocol deviations, necessary amendments, incorrectly gathered data and even inaccurate conclusions may increase.

    To develop a solid protocol:

    • A stepwise process must be followed involving various stakeholders at the right time
    • Crucial decisions need to be made to avoid possible pitfalls in a complex study design

    To learn more about protocol compliance with concrete examples:

  • Maxim#8 Ensuring Inspection Readiness at Clinical Facilities

    All clinical trial activities are required to follow Good Clinical Practice (GCP) principles.

    Compliance is regularly checked by regulatory authorities, via ad hoc inspections. Such inspections can be very stressful as all documentation needs to be complete and accurate, and there is always a fear that a non-compliance may be raised.

    The objectives of GCP inspections are to:

    • Verify that quality assurance arrangements exist, in compliance with regulatory requirements and GCP
    • Ensure the safety of human subjects was preserved and ethical standards applied
    • Verify that clinical trial data and results are scientifically valid and accurate

    The only way to avoid hectic preparation is to be inspection ready at all times. Discover how this can be achieved.

  • Maxim#9 Meaningful Data for Conclusive FIH/Phase 1 Trials

    Clinical trials are intended to find answers to a research question by generating data to prove or disprove a hypothesis.

    First-in-Human (FIH) and most Phase 1 trials by their very nature are exploratory, without a statistical hypothesis. They are aimed at obtaining reliable information on the safety, tolerability, pharmacokinetics and mechanism of action of a drug.

    Various data is captured from FIH trials. Despite their exploratory character, this data needs to be relevant, accurate and appropriately analyzed to obtain meaningful results that are useful for future clinical development.

    There are four main steps in clinical data processing:

    • Data Planning: Study Protocol, (e)CRF
    • Data Collection: Study Protocol/Manuals
    • Data Management: Data Management and Review Plan
    • Data Analysis: Statistical/PK Analysis Plan, MOCK TLFs

    To learn more about early phase clinical trial appropriate and reliable data with concrete examples:

  • Maxim#10 Bridging to Patient Clinical Trials

    Early phase clinical trials, known as human pharmacology studies, start principally with the aim of collecting information on the safety and tolerability of the drug product.

    However, the ultimate objective of a drug development program is to provide a medicine that is safe and shows positive benefit-risk balance for treatment of the target patient population.

    The following scientific aspects should carefully be studied and addressed during development of the study design for various early phase studies in patients, including:

    • To determine the safe dose range that could be used in early clinical studies in patients considering the dose to be well tolerated, but high enough to be effective
    • To discover and predict adverse events that could be foreseen, or possibly avoided, in patients, keeping in mind that patients are the target population for treatment
    • To establish and understand PK properties of the drug product (absorption, distribution, metabolism, and excretion; ADME), as early as possible in target patient population in order to use this knowledge to improve dosing regimen for a beneficial efficacy
    • To collect as much as possible PD and efficacy data in early patient trials to be more precisely prepared for late phase clinical development

    Two case studies discuss the input provided by SGS to two clients in the start-up of clinical trials in patients and in the management and conduct of those studies.